GLOBAL PHARMACEUTICAL MARKET

”

“The global pharmaceutical market value is expected to expand over $1.1 trillion USD by 2014,”

“

1. Growing at a CAGR of around 8%, the global pharmaceutical market is

forecasted to reach US$ 1043.4 Billion in 2012.

2. North America remains the largest pharmaceutical market constituting 42.8% of

the global sales in 2007. Growth in the region is however expected to slow down

in near future owing to patent expiration of key drugs and increased prevalence of

generics.

3. In Europe, growth in the top five markets is expected to remain sluggish in next

five years. Emerging markets in Central and Eastern Europe is however expected

to drive growth in future.

4. A large untapped population and strong economic growth in major countries is

expected to make Asia-Pacific the most lucrative pharmaceutical market in

future.

5. Growth in the Latin American markets is expected to be strong with Brazil and

Mexico amongst the most emerging pharmaceutical markets in the world.

6. Dwindling drug pipelines and patent expiration of a number of blockbuster drugs

may challenge the growth of global pharmaceutical market in future.

Type 1 diabetes: results from the body's failure to produce insulin, and presently requires the person to inject insulin. {OR insulin-dependent diabetes mellitus, (IDDM )} & juvenile diabetes.)

Type 2 diabetes: results from insulin resistance, a condition in which cells fail to use insulin properly, sometimes combined with an absolute insulin deficiency. {OR non-insulin-dependent diabetes mellitus, NIDDM)} & adult-onset diabetes.)

Gestational diabetes: is when pregnant women, who have never had diabetes before, have a high blood glucose level during pregnancy. It may precede development of type 2 DM.

There are three main types of diabetes:

Diabetes , is a group of metabolic diseases in which a person has high blood sugar, either because the body does not produce enough insulin, or because cells do not respond to the insulin that is produced.

• it is estimated that by 2030, this number will almost double.•It is more common (especially type 2) in the more developed countries. • it is expected that in Asia and Africa, where most patients will probably be found by 2030. •The increase in incidence of diabetes in developing countries follows the trend of urbanization and lifestyle changes, perhaps most importantly a "Western-style“ diet.

Globally as of 2010 it is estimated that there are 285 million people diabetes with type 2 making up about 90% of the cases.

GLOBAL DIABETES POPULATION

PREVALENCE OF DIABETES COUNTRY WISE

The global market for products in the management of

diabetes currently stands at $41 billion and is on pace to

grow to over $114 billion by 2018.

Oral anti-diabetics were the leading category of drugs

in 2010 and showed a growth rate of 6.3% from the total

global sales.

The total sales for insulin products increased

significantly as well.

GLOBAL DIABETES MARKET

USA controls more than 50% of the total Diabetes Drug market

share in 2009.

• Global Insulin Market is estimated to reach around US$ 17 Billion

by 2013.

• China will have the second highest Insulin market share by 2012

replacing Germany.

• DPP-IV Inhibitors is predicted to be more than US$ 5 Billion

market by 2015.

• LP-1 Agonists, market is forecasted to cross US$ 6 Billion mark

by 2015 .

• Novorapid is the blockbuster Insulin of Novo Nordisk it is

expected to cross US$ 3 Billion by 2015.

Global Diabetes Market Trends & Future Forecast

• Yet to launched Degludec and Degludec Plus is expected to be

blockbuster Insulin and cross US$ 4 Billion and US$ 6

Billion respectively by 2030.

• Januvia is proving a blockbuster of DPP – IV Inhibitors segment

expected to be more than US$ 4 Billion by 2017 .

•Last year launched Victoza and yet to be launched Exenatide

LAR is going to be blockbuster GLP-1 Agonists .

• China diabetes drug market has crossed the figure of Yuan 10

Billion by 2009.

• Japan Insulin market is expected to be more than US$ 1 Billion

by 2010.

Global Diabetes Market Trends & Future Forecast

Global DIABETES TOP PLAYERS

Anti-diabetic products include glucose meters, lancets, test strips,

continuous blood glucose meters, insulin, insulin pumps, syringes

and other insulin delivery devices and anti-diabetic drugs.

The bulk of product revenues come from three segments - test

strips, insulin and anti-diabetic drugs - which will remain the

largest sources of product revenues over the next ten years.

The most significant growth, however, will come from the nascent

segment of continuous blood glucose monitors, which provide

significantly added clinical benefit at only a modestly higher cost

compared to standard blood glucose meters.

PRODUCTS STRONG IN DIABETES MARKET

NEW MOLECULES DEVELOPING FOR DIABETES

University of Technology, Sydney. UTS researchers have identified molecules secreted by a parasitic worm that prevent the development of Type 1 diabetes in mice.A commercial version of the product is currently being developed for use in humans.

Researchers at the Stanford University School of Medicine have identified a key molecular pathway responsible for the natural decrease in the proliferation of insulin-producing cells that occurs as a person ages. Artificially activating this pathway, which is normally not functional in adults, may be a new way to combat diabetes.

INDIAN DIABETES MARKET

With around 51 million diabetic patients, India promises to be amongst the most lucrative diabetes markets in the world. In 2009, the total sales of insulin and non-insulin anti-diabetics reached $424 million, according to the findings of a news report added to the offering of Research and Markets.

REPORT HIGHLIGHTS

• A growing drug treated population coupled with the launch of several new drugs will drive the Indian diabetes market to $1.4 billion by 2015. • In 2009, the market for non-insulin anti-diabetics was worth $306 million. This represented a highly fragmented market with domestic diabetes care firm USV being the leading player with a 14% share. • USV’s Glycomet GP (glimepiride+metformin) was the leading drug in the non-insulin anti-diabetics market with sales worth nearly $10.5 million

INDIAN DIABETES MARKET

•The authors expect around 15 new drugs to be launched in the non-insulin anti-diabetics market in the next five years. Seven of them are expected to be in the DPP-IV inhibitor and GLP-1 agonist classes.

• The insulin market was worth $117 million in 2009. US health care major Abbott Laboratories was India's biggest player accounting for 61% of the total sales.

• Sanofi-Aventis’ Lantus (insulin glargine) represented one of the fastest growing drugs in the last five year and registered sales worth nearly $11 million in 2009

• The total number of diabetes patients in India is expected to reach 87 million by 2030. Around 56% of these patients will be from urban regions of the country.

INDIAN DIABETES TOP PLAYERS

THE INDIAN MARKETOPPORTUNITY

•World’s largest diabetes patient pool•Success of newly launched drugs•Increasing diagnosis and drug treated rates•A rapidly growing market In 2010, total sales of insulin and oral anti-diabetics in India reached INR 28 billion, of which, the market for oral anti-diabetics was worth INR 17 billion**. With the number of diabetics increasing, the market, over the next five years, will be driven by the strong uptake of insulin analogs.

Januvia is proving a blockbuster of DPP – IV Inhibitors segment

expected to be more than US$ 4 Billion by 2017 (GLOBALLY)